New And Special Drugs
-
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
-
Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
-
Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
-
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
-
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
-
Foundayo(Orforglipron) – Obesity/Overweight | HongKong DengYue Medicine
-
Exdensur (Depemokimab) – Eosinophilic Asthma | HongKong DengYue Medicine
-
Zometa (Zoledronic Acid) – HCM | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
What Are the Signs of Liver Cancer Getting Worse? Symptoms of Advanced Liver Cancer
Liver cancer is one of the most serious and life-threatening cancers worldwide. According to the International Agency for Research on Cancer (IARC), liver cancer remains
Silevimig Approved for Rabies Passive Immunization: The First Approved Bispecific Antibody for Rabies Prevention Worldwide
On June 22, 2026, China’s National Medical Products Administration (NMPA) officially approved Silevimig Injection (Jinsuxi®), independently developed by Genrix Biopharmaceutical, for rabies passive immunization in
Oral GLP-1 Drug Development Trends: Small-Molecule Innovation and Industry Competition
In recent years, GLP-1 receptor agonists (GLP-1 RAs) have become one of the most closely watched therapeutic areas in the global metabolic disease landscape. Among
RNA Therapeutics for Cardiovascular Disease: PCSK9, Lp(a) and Next-Gen Drug Pipeline (2026)
RNA therapeutics for cardiovascular disease are emerging as a transformative strategy for long-term disease management. Unlike traditional treatments that target proteins after they are produced,
China Approves the World’s First CAR-T Therapy for Solid Tumors: Satricabtagene Autoleucel for CLDN18.2-Positive Advanced Gastric Cancer
On June 22, 2026, China’s National Medical Products Administration (NMPA) approved Satricabtagene Autoleucel (Kailimei®), developed by CARsgen Therapeutics, for the treatment of patients with CLDN18.2-positive,
10 Key Questions Cancer Patients Ask: From Survival Rates to Treatment Options
Cancer treatment is often a long and uncertain journey. Global pharmaceutical distributor DengYueMed has organized the 10 key questions cancer patients ask to help patients
Izalontamab Brengitecan Approved in China: World’s First EGFR×HER3 Bispecific ADC, a Breakthrough in Nasopharyngeal Cancer
On June 22, 2026, NMPA officially approved Biokin Pharmaceutical’s independently developed Class 1 innovative drug, izalontamab brengitecan (brand name: Yizekang), for marketing in China. It
China API Industry Overview: Key Strength Areas, Supply Chain Capabilities, and Global Market Position
Over the past two decades, the China API industry has evolved into a foundational pillar of the global pharmaceutical ecosystem. 🌏 HongKong DengYue Medicine continues
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
